Years of Deep Expertise in Biologics Discovery
AI Drug Discovery & Development
Helping biotech and pharmaceutical companies bridge the gap between AI-generated therapeutic candidates and IND-enabling development. The platform combines AI candidate validation, high-throughput screening, developability assessment, pharmacology studies, and accelerated CMC activities within a single integrated workflow.
Artificial intelligence is transforming biologics discovery by enabling researchers to generate thousands of therapeutic antibody candidates in a fraction of the time required by traditional methods. However, AI-driven drug discovery programs often encounter critical challenges, including candidate validation bottlenecks, false-positive leads, limited developability data, and delays in transitioning promising molecules into preclinical development.
ProBio's AI Drug Discovery & Development Solution helps biotech and pharmaceutical companies overcome these hurdles through integrated high-throughput screening, developability assessment, pharmacology studies, and accelerated CMC strategies. By combining AI candidate validation with drug discovery and manufacturing expertise, ProBio enables faster, more confident selection of developable antibody candidates and accelerates progression toward IND-enabling studies.
From AI Candidates to IND Readiness
Comprehensive Screening Strategy: Balancing Functionality and Developability
Projects in Therapeutic Antibody
Projects in the Clinical Phase and Marketed
Solving the AIDD Validation Bottleneck, Closing the Gap to Pre-Clinical Development
Integrated Platform
Our integrated discovery platform streamlines the journey from expression through PK/Tox evaluation within a single workflow, enabling seamless program progression without the delays and complexity of multiple vendor handoffs. By consolidating critical development activities into one platform, teams can make faster, more informed decisions and accelerate candidate advancement.
Fast, High-Throughput & AI-Ready Data
Designed for speed and scalability, our platform delivers actionable results in as little as 10 days from gene to data. Automated high-throughput screening supports the processing of hundreds of samples daily, while customized, AI-ready data outputs and flexible reporting formats provide the structured insights needed for advanced analytics, predictive modeling, and data-driven decision-making.
Proven Discovery Expertise
Backed by extensive discovery experience, our team helps identify high-potential candidates through comprehensive functionality and developability screening. Established assays and validated animal models provide reliable data to assess key attributes early, reducing development risk and supporting confident progression toward clinical development.
Case Studies
Actionable Data in Under 10 Days
High-Throughput Functional Screening Identifies High-Quality Bispecific Antibody Leads in Days.
From Sequence to Tox-Ready Material in 4.5 Months
From AI Sequence to Pre-Tox in 4 Months: Accelerating Developability and CMC Readiness with PrepCMC and ExpressCMC.
Reducing Time to Tox-Ready Material
Accelerating Biologics CMC Development with Integrated Cell Line, Process, and Formulation Platforms.
Frequently Asked Questions
